Y-Biologics, Inc. (KOSDAQ:338840)

Market Cap	236.50B
Revenue (ttm)	5.96B
Net Income (ttm)	-6.19B
Shares Out	14.95M
EPS (ttm)	-499.76
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	198,614
Average Volume	505,115
Open	14,150
Previous Close	14,070
Day's Range	13,600 - 14,290
52-Week Range	5,330 - 15,180
Beta	n/a
RSI	70.71
Earnings Date	n/a

About Y-Biologics

Y-Biologics, Inc., an antibody new drug development platform company, engages in the research and development of immuno-oncology drugs and antibody drugs. It develops YBL-006, a PD-1 immune checkpoint inhibitor that is in clinical phase 1/2a medication for solid cancers. The company also develops mono-specific antibodies, such as YBL-011 and YBL-003 for solid cancers; YBL-013, an ALiCE antibody for solid cancers; and YBL-001, an anti-drug conjugate for small cell lung and liver cancers. Y-Biologics, Inc. was incorporated in 2007 and is headquar...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 338840

Financial Performance

In 2024, Y-Biologics's revenue was 5.76 billion, an increase of 65.64% compared to the previous year's 3.48 billion. Losses were -6.44 billion, -69.14% less than in 2023.